Analytical Data
-
Gene name
BTNL3
- Application
-
Alternative Names
(Butyrophilin-like receptor)
-
Species
Human
-
Source
E. coli
-
Tag
N- MBP & C- His-Avi
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6UXE8
-
Expression Region
18-237aa
-
Molecular Weight
72.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BTNL3 (butyrophilin-like 3) is a member of the butyrophilin family, which plays a crucial role in the immune system by regulating T cell responses. Previous studies have highlighted that BTNL3 is predominantly expressed in various immune tissues and is involved in modulating the activity of T cells and antigen-presenting cells. Its interaction with different receptors, including T cell receptors, suggests a significant role in maintaining immune tolerance and homeostasis. Research into BTNL3 has gained momentum due to its potential implications in autoimmune diseases, cancer immunotherapy, and transplantation. The unique structural features of BTNL3, such as its extracellular domain, make it an attractive target for therapeutic interventions aimed at enhancing or inhibiting immune responses. Recombination technology allows for the production of BTNL3 recombinant proteins, which can be used to study its function, interaction with immune cells, and role in disease contexts. This allows for exploration of its potential as a biomarker for disease progression or as a therapeutic target. Overall, the investigation of BTNL3 recombinant proteins is vital for understanding immune regulation and developing novel strategies in immunotherapy and disease management.
